Paragraph IV Gets A Date: FDA Will Announce When ANDAs Are Submitted
Executive Summary
FDA will begin posting the date when Paragraph IV applications are filed, FDA Commissioner McClellan told the Generic Pharmaceutical Association annual meeting March 2 in Boca Raton, Fla
You may also be interested in...
FDA First-Generic Notification Policy May Be Reviewed
FDA will re-examine whether it is legally barred from notifying a generic company early in the ANDA process that it is the first filer eligible for 180-day exclusivity, Chief Counsel Dan Troy said Sept. 30
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials